DK3302550T3 - Kombination af et anti-cd19 antistof og en brutons tyrosine kinase-inhibitor og anvendelse deraf - Google Patents

Kombination af et anti-cd19 antistof og en brutons tyrosine kinase-inhibitor og anvendelse deraf Download PDF

Info

Publication number
DK3302550T3
DK3302550T3 DK16725504T DK16725504T DK3302550T3 DK 3302550 T3 DK3302550 T3 DK 3302550T3 DK 16725504 T DK16725504 T DK 16725504T DK 16725504 T DK16725504 T DK 16725504T DK 3302550 T3 DK3302550 T3 DK 3302550T3
Authority
DK
Denmark
Prior art keywords
antibody
combination
tyrosine kinase
kinase inhibitor
bruton tyrosine
Prior art date
Application number
DK16725504T
Other languages
English (en)
Inventor
Jan Endell
Mark Winderlich
Rainer Boxhammer
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Application granted granted Critical
Publication of DK3302550T3 publication Critical patent/DK3302550T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
DK16725504T 2015-05-26 2016-05-25 Kombination af et anti-cd19 antistof og en brutons tyrosine kinase-inhibitor og anvendelse deraf DK3302550T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15169124 2015-05-26
EP15196860 2015-11-27
PCT/EP2016/061744 WO2016189014A1 (en) 2015-05-26 2016-05-25 Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof

Publications (1)

Publication Number Publication Date
DK3302550T3 true DK3302550T3 (da) 2019-11-04

Family

ID=56084030

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16725504T DK3302550T3 (da) 2015-05-26 2016-05-25 Kombination af et anti-cd19 antistof og en brutons tyrosine kinase-inhibitor og anvendelse deraf

Country Status (22)

Country Link
US (3) US10617691B2 (da)
EP (2) EP3302550B1 (da)
JP (3) JP6916741B2 (da)
KR (1) KR20180004286A (da)
CN (2) CN114601931B (da)
AU (3) AU2016266708B2 (da)
CA (1) CA2986175A1 (da)
CY (1) CY1122298T1 (da)
DK (1) DK3302550T3 (da)
ES (1) ES2754431T3 (da)
HK (1) HK1251152B (da)
HR (1) HRP20192100T1 (da)
HU (1) HUE046328T2 (da)
IL (2) IL255377B (da)
LT (1) LT3302550T (da)
PL (1) PL3302550T3 (da)
PT (1) PT3302550T (da)
RS (1) RS59605B1 (da)
RU (1) RU2756010C2 (da)
SI (1) SI3302550T1 (da)
WO (1) WO2016189014A1 (da)
ZA (1) ZA201707867B (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103842383B (zh) 2011-05-16 2017-11-03 健能隆医药技术（上海）有限公司 多特异性fab融合蛋白及其使用方法
CA3017776A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
CN116120454A (zh) * 2017-01-05 2023-05-16 上海煦顼技术有限公司 人源化抗cd19抗体及其与嵌合抗原受体的用途
EP3652206A1 (en) 2017-07-10 2020-05-20 International-Drug-Development-Biotech Treatment of b cell malignancies using afucosylated pro-apoptotic anti-cd19 antibodies in combination with anti cd20 antibodies or chemotherapeutics
CN112867735A (zh) * 2018-09-07 2021-05-28 亿一生物技术有限公司 双特异性抗原结合蛋白及其用途
KR20200030337A (ko) * 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
JP2023551519A (ja) * 2020-11-30 2023-12-08 インサイト・コーポレイション 抗ｃｄ１９抗体とパルサクリシブの組み合わせ療法
WO2022115120A1 (en) * 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
WO2024037594A1 (en) * 2022-08-19 2024-02-22 Beijing Innocare Pharma Tech Co., Ltd. Combination treatment with orelabrutinib and tafasitamab

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US20020058029A1 (en) 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
WO2003048731A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Antibody categorization based on binding characteristics
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
CA2611814A1 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
ES2365046T3 (es) 2005-12-30 2011-09-21 Merck Patent Gmbh Anticuerpos anti-cd19 con inmunogenicidad reducida.
WO2008022152A2 (en) 2006-08-14 2008-02-21 Xencor, Inc. Optimized antibodies that target cd19
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
SI2526934T1 (sl) 2006-09-22 2016-04-29 Pharmacyclics Llc Inhibitorji Bruton tirozin kinaze
EP2176298B1 (en) 2007-05-30 2017-11-15 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
HUE031533T2 (hu) 2007-10-19 2017-07-28 Seattle Genetics Inc CD19-kötõszerek valamint alkalmazásuk
WO2010095031A2 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
CA2765080C (en) 2009-06-24 2018-07-17 The Feinstein Institute For Medical Research Methods for treating chronic lymphocytic leukemia
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
US9073947B2 (en) 2011-06-10 2015-07-07 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
SI2744826T1 (sl) * 2011-08-16 2022-05-31 Morphosys Ag Kombinirana terapija s protitelesom proti CD19 in analogom purina
KR20200058583A (ko) * 2011-08-16 2020-05-27 모르포시스 아게 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
TWI573792B (zh) * 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
EP2890691B1 (en) * 2012-08-31 2018-04-25 Principia Biopharma Inc. Benzimidazole derivatives as itk inhibitors
WO2014113932A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors

Also Published As

Publication number Publication date
IL255377A (en) 2018-02-28
JP2018516905A (ja) 2018-06-28
IL287433A (en) 2021-12-01
WO2016189014A1 (en) 2016-12-01
HRP20192100T1 (hr) 2020-02-21
AU2024201029A1 (en) 2024-03-14
US20180153892A1 (en) 2018-06-07
PT3302550T (pt) 2019-11-26
RU2017143166A3 (da) 2019-11-28
ES2754431T3 (es) 2020-04-17
CN114601931A (zh) 2022-06-10
CA2986175A1 (en) 2016-12-01
JP6916741B2 (ja) 2021-08-11
AU2022202796B2 (en) 2023-11-23
KR20180004286A (ko) 2018-01-10
JP2021152029A (ja) 2021-09-30
US20240009196A1 (en) 2024-01-11
AU2016266708A1 (en) 2017-11-16
JP2023058502A (ja) 2023-04-25
PL3302550T3 (pl) 2020-02-28
CN107660151A (zh) 2018-02-02
RS59605B1 (sr) 2020-01-31
EP3603672A1 (en) 2020-02-05
US20200206228A1 (en) 2020-07-02
RU2756010C2 (ru) 2021-09-24
US10617691B2 (en) 2020-04-14
HUE046328T2 (hu) 2020-03-30
HK1251152B (zh) 2020-04-24
LT3302550T (lt) 2019-11-11
AU2016266708B2 (en) 2022-02-03
CY1122298T1 (el) 2021-01-27
CN107660151B (zh) 2022-03-11
EP3302550A1 (en) 2018-04-11
EP3302550B1 (en) 2019-08-28
CN114601931B (zh) 2023-09-01
AU2022202796A1 (en) 2022-05-19
SI3302550T1 (sl) 2020-01-31
RU2017143166A (ru) 2019-06-27
IL255377B (en) 2021-12-01
ZA201707867B (en) 2021-03-31

Similar Documents

Publication Publication Date Title
DK3302550T3 (da) Kombination af et anti-cd19 antistof og en brutons tyrosine kinase-inhibitor og anvendelse deraf
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
DK3368069T3 (da) Anvendelse af myostatininhibitorer og kombinationsterapier
DK3468966T3 (da) Inhibitorer af menin-mll-interaktionen
DK3303334T3 (da) Tyrosinkinasehæmmere
DK3653221T3 (da) Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
DK3303395T3 (da) Anti-cd40-antistoffer og anvendelser deraf
DK3205650T3 (da) Egfr-hæmmer og fremstilling og anvendelse deraf
DK3185868T3 (da) Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme
DK3423451T3 (da) Inhibitorer af wdr5-protein-proteinbinding
MA42623A (fr) Inhibiteurs de la tyrosine kinase de bruton
DK3227310T3 (da) Heterobifunktionelle inhibitorer af e-selektiner og cxcr4-kemokin-receptorer
DK3003699T3 (da) Fodtøjsgenstand og fremgangsmåden til dannelse af genstanden
KR102068915B9 (ko) 조직 인자 경로 억제제 항체 및 그의 용도
MA41350A (fr) Synthèse d'un inhibiteur de la tyrosine kinase de bruton
DK3651768T3 (da) Heterocykliske inhibitorer af atr-kinase
DK3571192T3 (da) Jak1-selektive inhibitorer
DK3691620T3 (da) P38-kinaseinhibitor reducerer dux4- og downstream-gen-ekspression til behandling af fshd
DK3621694T3 (da) Lrrc33-inhibitorer og anvendelse heraf
DK3630744T3 (da) Pyrazol-magl-inhibitorer
DK3719021T3 (da) Inhibitorer af adapterassocieret kinase 1, sammensætninger omfattende disse og fremgangsmåder til anvendelse deraf
DK3532098T3 (da) Kombination af anti-cd19-antistof med en bcl-2-inhibitor og anvendelser deraf
DK3304639T3 (da) Excitation og anvendelse af førte overfladebølger
DK3474883T3 (da) Komplementinhibitorer og anvendelser deraf
DK3280405T3 (da) Inhibitorer og anvendelser deraf